Fluoxetine & Bupropion Interaction

Fluoxetine (an SSRI) and bupropion (a norepinephrine-dopamine reuptake inhibitor) are sometimes prescribed together as a combination strategy for treatment-resistant depression. While this combination may be clinically appropriate under careful supervision, it carries significant interaction risks that require close monitoring.

Fluoxetine and its active metabolite norfluoxetine are potent inhibitors of CYP2B6, the primary enzyme responsible for metabolizing bupropion. This inhibition can substantially increase bupropion plasma levels, raising the risk of dose-dependent adverse effects, particularly seizures.

This combination should only be used when the potential benefits outweigh the risks, typically in patients who have not responded to monotherapy with either agent. Lower doses of bupropion are recommended when used concurrently with fluoxetine.

Fluoxetine and its active metabolite norfluoxetine are potent inhibitors of CYP2B6, the principal cytochrome P450 enzyme responsible for the hydroxylation of bupropion to its active metabolite hydroxybupropion. Inhibition of CYP2B6 leads to increased plasma concentrations of the parent compound bupropion and decreased formation of hydroxybupropion. Elevated bupropion levels are associated with a dose-dependent increase in seizure risk. Additionally, both fluoxetine and bupropion increase serotonergic and noradrenergic neurotransmission, creating a theoretical risk of serotonergic excess, though bupropion has minimal direct serotonergic activity.

This is a clinically significant interaction. The bupropion prescribing information reports a seizure incidence of approximately 0.4% at doses up to 450 mg/day, with the risk increasing sharply at higher plasma concentrations. CYP2B6 inhibition by fluoxetine can effectively increase bupropion exposure, mimicking the pharmacokinetics of a higher dose. Case reports have documented seizures in patients taking this combination at otherwise standard doses. The interaction is further complicated by fluoxetine's long half-life (1-3 days for fluoxetine, 4-16 days for norfluoxetine), meaning the inhibitory effect persists for weeks after fluoxetine discontinuation.

If the combination is deemed necessary, use the lowest effective dose of bupropion, typically not exceeding 150 mg twice daily. Avoid bupropion SR/XL formulations above 300 mg/day when combined with fluoxetine. Titrate bupropion slowly. Counsel patients about seizure precautions: maintain regular sleep schedules, avoid excessive alcohol, ensure adequate nutrition, and report any new neurological symptoms immediately. When discontinuing fluoxetine, maintain lower bupropion doses for several weeks due to the prolonged half-life of norfluoxetine.

Monitor for signs of bupropion toxicity: tremor, agitation, insomnia, seizures. Monitor for serotonergic effects: agitation, myoclonus, hyperreflexia, diaphoresis. Assess seizure risk factors in each patient before initiating combination therapy (history of seizures, eating disorders, alcohol use, head trauma). Monitor blood pressure, as both agents can increase blood pressure.

For treatment-resistant depression, alternatives to this combination include switching to a different antidepressant class (SNRI such as venlafaxine or duloxetine), augmentation with aripiprazole or lithium, or augmentation with mirtazapine. If bupropion is needed for smoking cessation in a patient on fluoxetine, consider nicotine replacement therapy or varenicline as alternatives.